NeuroCure Receives Continued Funding – Excellence Cluster Strengthens Neurosciences in Berlin

With the decision of May 22, NeuroCure will continue to receive funding in the upcoming funding period as part of the Excellence Strategy. This enables the successful work in researching neurological and psychiatric diseases to be continued and further expanded.

Since 2007, scientists from both clinical and basic research have been working together in the cluster in an interdisciplinary manner to better understand the complex mechanisms of the brain and the causes of numerous diseases. The focus is not only on individual disease patterns, but above all on overarching pathophysiological processes that may play a role in various neurological and psychiatric disorders.

The research projects span all phases of life – from brain development and homeostasis to the aging process. Topics such as stroke, multiple sclerosis, dementia, epilepsy, movement disorders, autism, schizophrenia, depression, and addiction are addressed, as well as rare and acute diseases. The goal is to rapidly translate findings from basic research into clinical application, thus developing new diagnostic and therapeutic approaches.

A distinctive feature of NeuroCure is the close integration of basic science and clinical research. Innovative programs, central research platforms, and new structures promote collaboration and accelerate the translation of research findings into practice.

“The continued funding is a tremendous recognition of our teamwork and opens up new opportunities to further advance the research and treatment of neurological and psychiatric diseases. My heartfelt thanks go to all partners and supporters for their trust,” said Prof. Dr. Dietmar Schmitz, spokesperson of the cluster.

With this renewed funding, NeuroCure will further expand its research areas, advance the investigation of innovative gene and cell therapies, initiate new collaborations, and strengthen Berlin’s international visibility in the field of translational neuroscience.